Skip to main content
Livermore
Livermore
ZHEN

Lasry Marc

SEC CIK
0001259927
Latest filing
Nov 14, 2025

The latest 13F from Lasry Marc covers Q3 2025 (filed Nov 14, 2025): 9 long positions worth $15.1M. The top 10 holdings make up 100.0% of the portfolio, and the largest is XBP Global Holdings, Inc. (XBP) at 64.9%. Livermore has 21 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2025

Share counts compared with Q2 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
3
Est. +$12.4M
Added
0
Reduced
0
Sold out
2
Est. −$14.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. XBPXBP Global Holdings, Inc.
    64.9%$9.77MHistory
  2. HYPDHyperion Defi, Inc.
    15.3%$2.30MHistory
  3. NEXTNextDecade Corp
    11.5%$1.73MHistory
  4. DRIODarioHealth Corp.
    2.7%$403.3KHistory
  5. VBIOValion Bio, Inc.
    2.0%$293.7KHistory

Biggest buys

New and added positions, by estimated amount bought

  1. XBPXBP Global Holdings, Inc.
    +$9.77MNewHistory
  2. HYPDHyperion Defi, Inc.
    +$2.30MNewHistory
  3. VBIOValion Bio, Inc.
    +$293.7KNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. XBPXBP Global Holdings, Inc.
    +64.89 pp0.0% → 64.9%History
  2. HYPDHyperion Defi, Inc.
    +15.28 pp0.0% → 15.3%History
  3. VBIOValion Bio, Inc.
    +1.95 pp0.0% → 2.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. Pinduoduo Inc722304AC6
    −$14.6MSold out
  2. Exela Technologies, Inc.30162V607
    −$16.3KSold out

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. Pinduoduo Inc722304AC6
    −81.61 pp81.6% → 0.0%
  2. Exela Technologies, Inc.30162V607
    −0.09 pp0.1% → 0.0%

Metrics

13F metrics for Q3 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$15.1M
−$2.82M (−15.8%) vs. prior quarter
Positions
9
+1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
75.1%
Q3 2025, one quarter
Average holding period
2.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $216.7M (Q2 2021)

Q1 2021: $144.9MQ2 2021: $216.7MQ3 2021: $161.8MQ4 2021: $202.5MQ1 2022: $201.1MQ2 2022: $65.7MQ3 2022: $52.0MQ4 2022: $64.4MQ1 2023: $52.1MQ2 2023: $77.3MQ3 2023: $101.4MQ4 2023: $67.7MQ1 2024: $117.5MQ2 2024: $101.2MQ3 2024: $55.0MQ4 2024: $22.5MQ1 2025: $21.8MQ2 2025: $17.9MQ3 2025: $15.1M
Q1 2021Q3 2025
13F filings of Lasry Marc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2025Nov 14, 20259$15.1MXBPHYPDNEXTvs. Q2 2025SEC
Q2 2025Aug 15, 20258$17.9MPinduoduo IncNEXTDRIOvs. Q1 2025SEC
Q1 2025May 14, 202510$21.8MPinduoduo IncALXNEXTvs. Q4 2024SEC
Q4 2024Feb 14, 202511$22.5MPinduoduo IncALXNEXTvs. Q3 2024SEC
Q3 2024Nov 14, 202410$55.0MNEXTPinduoduo IncALXvs. Q2 2024SEC
Q2 2024Aug 14, 202411$101.2MNEXTTALOFYBRvs. Q1 2024SEC
Q1 2024May 15, 202411$117.5MNEXTTALOSTRvs. Q4 2023SEC
Q4 2023Feb 14, 202410$67.7MNEXTSTRFYBRvs. Q3 2023SEC
Q3 2023Nov 14, 202313$101.4MNEXTSDRLSTRvs. Q2 2023SEC
Q2 2023Aug 14, 202312$77.3MSDRLAMPYSTRvs. Q1 2023SEC
Q1 2023Jun 6, 2023Amended10$52.1MAMPYSTRFYBRvs. Q4 2022SEC
Q4 2022Feb 14, 202311$64.4MAMPYSTRFYBRvs. Q3 2022SEC
Q3 2022Nov 14, 202211$52.0MAMPYRealogy Grp LLC/Realogy CoFYBRvs. Q2 2022SEC
Q2 2022Aug 15, 202211$65.7MAMPYRealogy Grp LLC/Realogy CoALXvs. Q1 2022SEC
Q1 2022Jun 15, 2022Amended14$201.1MDOVSTAMPYvs. Q4 2021SEC
Q4 2021Feb 14, 20229$202.5MVSTViacomcbs IncGPORvs. Q3 2021SEC
Q3 2021Nov 15, 20219$161.8MVSTAMPYGPORvs. Q2 2021SEC
Q2 2021Aug 16, 202111$216.7MVSTEXEGPORvs. Q1 2021SEC
Q1 2021May 17, 20216$144.9MVSTRIGAMPY–SEC

13D and 13G filings

Companies where Lasry Marc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Lasry Marc does not currently report owning 5% or more of any company.

Latest filings

13 filings on file made by Lasry Marc or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Lasry Marc
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
HYPDHyperion Defi, Inc.Sep 19, 20259:45 AM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A4.20%240.1K shares−2.00 ppfrom 6.20%Below 5%Sep 17, 2025SEC
HYPDHyperion Defi, Inc.Sep 17, 20253:36 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A6.20%354.3K shares−2.33 ppfrom 8.53%Sep 12, 2025SEC
CALCCalciMedica, Inc.Sep 9, 20254:26 PM ETAvenue Venture Opportunities Fund II, L.P.and 4 others13G/A8.87%1.36M shares0.00 ppfrom 8.87%Sep 1, 2025SEC
CALCCalciMedica, Inc.Sep 2, 20257:10 PM ETAvenue Venture Opportunities Fund II, L.P.and 4 others13G/A8.87%1.36M shares+2.17 ppfrom 6.70%Sep 1, 2025SEC
XBPXBP Global Holdings, Inc.Aug 5, 20258:45 PM ETAvenue RP Opportunities Fund, L.P.and 11 others13D10.30%12.1M sharesNewJul 29, 2025SEC
HYPDHyperion Defi, Inc.Jul 2, 20254:49 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A8.53%435.4K shares−1.46 ppfrom 9.99%Jun 24, 2025SEC
HYPDHyperion Defi, Inc.Jun 20, 20254:01 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A9.99%435.4K shares0.00 ppfrom 9.99%Jun 17, 2025SEC
HYPDHyperion Defi, Inc.Jun 13, 20252:54 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A9.99%435.4K shares0.00 ppfrom 9.99%Jun 11, 2025SEC
HYPDHyperion Defi, Inc.Jun 3, 20259:15 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D/A9.99%5.98M shares−57.91 ppfrom 67.90%Jan 31, 2025SEC
CALCCalciMedica, Inc.May 28, 20256:55 PM ETAvenue Venture Opportunities Fund II, L.P.and 4 others13G6.70%1.00M sharesNewFeb 28, 2025SEC
CTSOCytosorbents CorpMay 28, 20256:47 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13G5.70%3.76M sharesNewJun 26, 2024SEC
HYPDHyperion Defi, Inc.May 15, 20255:09 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13D67.90%5.98M sharesNewFeb 21, 2025SEC
XAIRBeyond Air, Inc.Feb 4, 20257:24 PM ETAvenue Venture Opportunities Fund, L.P.and 7 others13G/A8.86%8.07M shares–Dec 31, 2024SEC